Persistent Asset Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Persistent Asset Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-204	Closed	-$11.9K	–	364
2025 Q3	$11.9K	Hold	204	–	–	0.01%	214
2025 Q2	$40.6K	Buy	+204	New	+$3.79K	0.03%	150

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Persistent Asset Partners's ACAD Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 715 shares worth $18.1K. The stake represents 0.01% of the portfolio and ranks #625 among its holdings.

354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Persistent Asset Partners held 715 shares of Acadia Pharmaceuticals worth $18.1K as of Q2 2026.
Acadia Pharmaceuticals was a new Persistent Asset Partners position in Q2 2026.
Acadia Pharmaceuticals made up 0.01% of Persistent Asset Partners's portfolio in Q2 2026, its #625 holding.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.